Business Model & Strategy

OCT Company Presentation

Business Model

OCTP is a well-established, innovative, and growing pharmaceutical company developing a portfolio of next-generation prescription cannabinoid medicines for approval by key regulatory agencies worldwide, including the FDA, EMA, and MHRA, targeting the multi-billion dollar pain market.

Since inception in 2017, OCTP has operated a partnership model with an extensive network of external academic and commercial partners including Evotec SE, Voisin Consulting SARL, Canopy Growth Corporation and the University of Oxford.

Strategy

OCTP has established a pipeline of three types of cannabinoid compounds, from which it is developing medicines that  target the endocannabinoid system and address significant unmet medical needs including rare diseases:

• Phytocannabinoids, the same compounds found in cannabis (pCBs);
• Chemically modified pCBs with improved drug-like characteristics, and;
• Novel chemical entities (NCEs) with receptor selectivity.

This three-pronged strategy enables the Group to balance risk, value and time to market, whilst ensuring market exclusivity and strong patent protection around all its key activities.

We have developed a proprietary library of 427 synthetic cannabinoid derivatives and around 14 patent families, providing a source for further drug candidates to enter our pipeline. The library of compounds is screened by academic or commercial partners in disease model assays. The chemical modification of the cannabinoid creates a new compound with the potential for protection under composition of matter patents that we believe can be used by the Group to target common indications in addition to rare diseases.

Due to the highly patentable nature of OCT’s derivative compounds, we believe that a wide range of pain-related indications can be targeted by the Group. In addition, by employing an orphan indication strategy, OCT can also utilise unmodified pCBs and other off-patent compounds to target a group of rare diseases that would not otherwise be approached, and where exclusivity can be obtained.

We may also in-licence any of the three types of compounds set out above. In-licensing drug candidates that have passed one or more stages in development provides the Group with an opportunity to advance its drug pipeline more quickly. In-licensing can also be used to diversify a drug pipeline and to target both large and orphan indications.

Company Information

OCT is incorporated under the laws of England and Wales under the Companies Act 2006 and the company number 13179529. The Company’s main country of operations is the United Kingdom, where it is headquartered.

<sup>1. Food and Drug Administration
2. European Medicines Agency
3. Medicines and Healthcare products Regulatory Agency</sup>